0.000USD0.000Pre-market 08/03, 09:30 (ET)
857.31MMarket Cap
5.23P/E TTM
Key Figures
4.400Open
4.449High
1.17MVolume
5.23P/E TTM
LossP/E Dynamic
--Dividend TTM
0.59%Turnover Ratio
4.410Prev. Close
4.270Low
3.62MTurnover
LossP/E Static
3.29P/B
0.00%Div Yield TTM
81.55%ROA
5.10052wk High
1.03Volume Ratio
-69.92MNet Profit
196.95MShares
0.8295EPS TTM
0.63Beta
94.73%ROE
3.04052wk Low
4.07%Amplitude
100.00%Gross Margin
857.31MMarket Cap
-4.04Reward/Risk
2.79%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Arbutus Biopharma Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 5.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Arbutus Biopharma Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Arbutus Biopharma Corp Highlights
StrengthsRisks
Arbutus Biopharma Corp News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Arbutus Biopharma Corp
ABUS
2
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Arbutus Biopharma Corp Info
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Ticker SymbolABUS
CompanyArbutus Biopharma Corp
CEOAndroski (Lindsay)
Websitehttps://www.arbutusbio.com/
Shareholders
FAQs
What is the current price of Arbutus Biopharma Corp (ABUS)?
The current price of Arbutus Biopharma Corp (ABUS) is 4.34.
What is the symbol of Arbutus Biopharma Corp?
The ticker symbol of Arbutus Biopharma Corp is ABUS.
What is the 52-week high of Arbutus Biopharma Corp?
The 52-week high of Arbutus Biopharma Corp is 5.10.
What is the 52-week low of Arbutus Biopharma Corp?
The 52-week low of Arbutus Biopharma Corp is 3.04.
What is the market capitalization of Arbutus Biopharma Corp?
The market capitalization of Arbutus Biopharma Corp is 857.31M.
Is Arbutus Biopharma Corp (ABUS) currently rated as Buy, Hold, or Sell?
According to analysts, Arbutus Biopharma Corp (ABUS) has an overall rating of STRONG BUY, with a price target of 5.50.
What is the Earnings Per Share (EPS TTM) of Arbutus Biopharma Corp (ABUS)?
The Earnings Per Share (EPS TTM) of Arbutus Biopharma Corp (ABUS) is -0.17.
